ECSP045217A - DERIVATIVES OF N-BIFENILMETIL AMINOCICLOALCANCARBOXAMIDA WITH A SUBSTITUTE IN THE METHYL, USEFUL AS AN ANTIGONIST OF BRADICININA - Google Patents
DERIVATIVES OF N-BIFENILMETIL AMINOCICLOALCANCARBOXAMIDA WITH A SUBSTITUTE IN THE METHYL, USEFUL AS AN ANTIGONIST OF BRADICININAInfo
- Publication number
- ECSP045217A ECSP045217A EC2004005217A ECSP045217A ECSP045217A EC SP045217 A ECSP045217 A EC SP045217A EC 2004005217 A EC2004005217 A EC 2004005217A EC SP045217 A ECSP045217 A EC SP045217A EC SP045217 A ECSP045217 A EC SP045217A
- Authority
- EC
- Ecuador
- Prior art keywords
- useful
- methyl
- derivatives
- bradicinina
- bifenilmetil
- Prior art date
Links
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical class [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 title 1
- 101800004538 Bradykinin Proteins 0.000 abstract 2
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract 2
- 102100035792 Kininogen-1 Human genes 0.000 abstract 2
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract 2
- 206010061218 Inflammation Diseases 0.000 abstract 1
- 239000000556 agonist Substances 0.000 abstract 1
- 239000005557 antagonist Substances 0.000 abstract 1
- 230000004054 inflammatory process Effects 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 238000006467 substitution reaction Methods 0.000 abstract 1
- 208000024891 symptom Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
- C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D257/04—Five-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/24—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atom of at least one of the carboxamide groups bound to a carbon atom of a ring other than a six-membered aromatic ring of the carbon skeleton
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/455—Nicotinic acids, e.g. niacin; Derivatives thereof, e.g. esters, amides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/10—Drugs for disorders of the urinary system of the bladder
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/78—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D213/81—Amides; Imides
- C07D213/82—Amides; Imides in position 3
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
- C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
- C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Neurology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Vascular Medicine (AREA)
- Gastroenterology & Hepatology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Cardiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Los derivados N-bifenilo (con sustitución con metilo) de la aminocicloalcancarboxamida son antagonistas o agonistas inversos de la bradicinina B1, útiles en el tratamiento o la prevención de síntomas, tales como dolor e inflamación, asociados con el pasaje de la bradicinina B1.The N-biphenyl derivatives (with methyl substitution) of the aminocycloalkanecarboxamide are antagonists or inverse agonists of bradykinin B1, useful in the treatment or prevention of symptoms, such as pain and inflammation, associated with the passage of bradykinin B1.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35506202P | 2002-02-08 | 2002-02-08 | |
| US41017202P | 2002-09-12 | 2002-09-12 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ECSP045217A true ECSP045217A (en) | 2004-09-28 |
Family
ID=27737481
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| EC2004005217A ECSP045217A (en) | 2002-02-08 | 2004-08-02 | DERIVATIVES OF N-BIFENILMETIL AMINOCICLOALCANCARBOXAMIDA WITH A SUBSTITUTE IN THE METHYL, USEFUL AS AN ANTIGONIST OF BRADICININA |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US6919343B2 (en) |
| EP (1) | EP1501787B1 (en) |
| JP (1) | JP4098249B2 (en) |
| KR (1) | KR20040083440A (en) |
| CN (1) | CN1328247C (en) |
| AR (1) | AR038377A1 (en) |
| AT (1) | ATE309202T1 (en) |
| AU (1) | AU2003216169B2 (en) |
| BR (1) | BR0307508A (en) |
| CA (1) | CA2474373C (en) |
| DE (1) | DE60302240T2 (en) |
| DK (1) | DK1501787T3 (en) |
| EA (1) | EA007297B1 (en) |
| EC (1) | ECSP045217A (en) |
| ES (1) | ES2250899T3 (en) |
| HR (1) | HRP20040677A2 (en) |
| IS (1) | IS7372A (en) |
| JO (1) | JO2356B1 (en) |
| MA (1) | MA27108A1 (en) |
| MX (1) | MXPA04007660A (en) |
| NO (1) | NO20043739L (en) |
| NZ (1) | NZ534062A (en) |
| PE (1) | PE20030986A1 (en) |
| PL (1) | PL371664A1 (en) |
| RS (1) | RS65404A (en) |
| TW (1) | TWI259079B (en) |
| WO (1) | WO2003066577A1 (en) |
Families Citing this family (30)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002367427A1 (en) * | 2001-12-28 | 2003-07-24 | Takeda Chemical Industries, Ltd. | Biaryl compound and use thereof |
| DE60303441T2 (en) * | 2002-02-08 | 2006-09-21 | Merck & Co., Inc. | N-BIPHENYLMETHYLAMINOCYCLOALKANCARBOXAMID-DERIVATIVE |
| IL166426A0 (en) * | 2002-08-29 | 2006-01-15 | Merck & Co Inc | N-biarylmethyl aminocycloalkanecarboxamide derivatives |
| CA2509881A1 (en) * | 2002-12-19 | 2004-07-08 | Elan Pharmaceuticals, Inc. | Substituted n-phenyl sulfonamide bradykinin antagonists |
| US7332499B2 (en) * | 2003-08-07 | 2008-02-19 | Merck & Co., Inc. | Sulfonyl substituted n-(biarylmethyl) aminocyclopropanecarboxamides |
| WO2005063690A1 (en) * | 2003-12-22 | 2005-07-14 | Merck & Co., Inc. | Alpha-hydroxy amides as bradykinin antagonists or inverse agonists |
| CA2557858A1 (en) * | 2004-03-02 | 2005-09-15 | Merck & Co., Inc. | Amino cyclopropane carboxamide derivatives as bradykinin antagonists |
| US20050245543A1 (en) * | 2004-04-30 | 2005-11-03 | Pfizer Inc | Histamine-3 receptor antagonists |
| US20060024241A1 (en) * | 2004-08-02 | 2006-02-02 | Bebaas, Inc. | Vitamin B12 compositions |
| DE102004060542A1 (en) * | 2004-12-16 | 2006-07-06 | Sanofi-Aventis Deutschland Gmbh | Hydroxybiphenyl carboxylic acids and derivatives, process for their preparation and their use |
| NZ555334A (en) | 2004-12-24 | 2010-05-28 | Spinifex Pharm Pty Ltd | Method of treatment or prophylaxis of a neuropathic condition using AT2 receptor antagonist |
| US20130131007A1 (en) | 2005-09-07 | 2013-05-23 | Bebaas, Inc. | Vitamin b12 compositions |
| US20070178141A1 (en) * | 2005-09-07 | 2007-08-02 | Bebaas, Inc. | Vitamin B12 compositions |
| JP5230595B2 (en) * | 2006-03-20 | 2013-07-10 | スピニフェクス ファーマシューティカルズ ピーティーワイ リミテッド | Methods for treating or preventing inflammatory pain |
| US8945505B2 (en) * | 2007-02-02 | 2015-02-03 | Panaphix, Inc. | Use of arsenic compounds for treatment of pain and inflammation |
| ES2569660T3 (en) | 2007-06-08 | 2016-05-12 | Mannkind Corporation | IRE-1alpha inhibitors |
| CL2008002545A1 (en) * | 2007-08-29 | 2009-10-23 | Boehringer Ingelheim Int | Phenoxy-benzyl-carbamoyl derived compounds; pharmaceutical composition; process for preparing the pharmaceutical composition; and its use in the treatment of pain. |
| CA2722704A1 (en) * | 2008-04-28 | 2009-11-05 | Zalicus Pharmaceuticals Ltd. | Cyclylamine derivatives as calcium channel blockers |
| WO2010097373A1 (en) * | 2009-02-26 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Compounds for use as bradykinin b1 antagonists |
| WO2010097374A1 (en) * | 2009-02-26 | 2010-09-02 | Boehringer Ingelheim International Gmbh | Compounds for use as bradykinin b1 antagonists |
| PT2401256E (en) * | 2009-02-26 | 2013-05-13 | Boehringer Ingelheim Int | Compounds as bradykinin b1 antagonists |
| US10457810B2 (en) | 2009-08-24 | 2019-10-29 | Board Of Trustees Of Michigan State University | Densified biomass products containing pretreated biomass fibers |
| MA34008B1 (en) * | 2010-02-23 | 2013-02-01 | Boehringer Ingelheim Int | COMPOUNDS AS ANTAGONISTS OF BRADYKININ B1 |
| AU2011242896C1 (en) | 2010-04-19 | 2016-04-21 | Board Of Trustees Of Michigan State University | Digestible lignocellulosic biomass and extractives and methods for producing same |
| US8937073B2 (en) * | 2010-08-20 | 2015-01-20 | Boehringer Ingelheim International Gmbh | Disubstituted tetrahydrofuranyl compounds and their use as B1-receptor antagonists |
| HUP1000598A2 (en) * | 2010-11-05 | 2012-09-28 | Richter Gedeon Nyrt | Indole derivatives |
| US8912221B2 (en) * | 2010-12-27 | 2014-12-16 | Hoffmann-La Roche Inc. | Biaryl amide derivatives |
| US8592426B2 (en) * | 2011-01-24 | 2013-11-26 | Hoffmann—La Roche Inc. | Aryl-benzocycloalkyl amide derivatives |
| JP2021501785A (en) * | 2017-11-02 | 2021-01-21 | カリコ ライフ サイエンシーズ エルエルシー | Modulator of integrated stress pathway |
| TW202545902A (en) | 2018-10-11 | 2025-12-01 | 美商嘉來克生命科學有限責任公司 | Prodrug modulators of the integrated stress pathway |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270317A (en) * | 1990-03-20 | 1993-12-14 | Elf Sanofi | N-substituted heterocyclic derivatives, their preparation and the pharmaceutical compositions in which they are present |
| IL99372A0 (en) | 1990-09-10 | 1992-08-18 | Ciba Geigy Ag | Azacyclic compounds |
| US5208236A (en) * | 1992-09-23 | 1993-05-04 | Schering Corporation | N-(acylaminomethyl)glutaryl amino acids and use |
| ATE193706T1 (en) | 1993-11-16 | 2000-06-15 | Novartis Ag | CYCLIC AMINO ACID DERIVATIVES WITH ACE AND NEP INHIBITING ACTIVITY |
| AU7211696A (en) | 1995-09-27 | 1997-04-17 | Ciba-Geigy Ag | Treatment of chronic progressive renal failure |
| US6433185B1 (en) * | 1996-01-11 | 2002-08-13 | Sanofi-Synthelabo | N-(arylsulphonyl) amino acid derivatives, process for their preparation and pharmaceutical compositions containing them |
| FR2743562B1 (en) * | 1996-01-11 | 1998-04-03 | Sanofi Sa | N- (ARYLSULFONYL) AMINO ACID DERIVATIVES, THEIR PREPARATION, THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
| ATE288922T1 (en) | 1998-04-23 | 2005-02-15 | Novartis Pharma Gmbh | CERTAIN HETEROARYL SUBSTITUTED THIOL INHIBITORS OF ENDOTHELIN ALTERNATE ENZYMES |
| EP1073674A1 (en) | 1998-04-23 | 2001-02-07 | Novartis AG | Thiol inhibitors of endothelin-converting enzyme |
| US20020052370A1 (en) | 2000-07-06 | 2002-05-02 | Barber Christopher Gordon | Cyclopentyl-substituted glutaramide derivatives as inhibitors of neutral endopeptidase |
| DE10036121A1 (en) | 2000-07-25 | 2002-02-07 | Merck Patent Gmbh | N-Substituted-1-amino-1,1-dialkyl-carboxylic acid derivatives |
| DE60303441T2 (en) | 2002-02-08 | 2006-09-21 | Merck & Co., Inc. | N-BIPHENYLMETHYLAMINOCYCLOALKANCARBOXAMID-DERIVATIVE |
-
2003
- 2003-01-30 TW TW092102107A patent/TWI259079B/en not_active IP Right Cessation
- 2003-01-30 US US10/354,674 patent/US6919343B2/en not_active Expired - Lifetime
- 2003-01-30 AR ARP030100276A patent/AR038377A1/en not_active Application Discontinuation
- 2003-02-04 NZ NZ534062A patent/NZ534062A/en unknown
- 2003-02-04 DE DE60302240T patent/DE60302240T2/en not_active Expired - Lifetime
- 2003-02-04 AU AU2003216169A patent/AU2003216169B2/en not_active Ceased
- 2003-02-04 KR KR10-2004-7012238A patent/KR20040083440A/en not_active Withdrawn
- 2003-02-04 BR BR0307508-7A patent/BR0307508A/en not_active IP Right Cessation
- 2003-02-04 CN CNB03803560XA patent/CN1328247C/en not_active Expired - Fee Related
- 2003-02-04 EP EP03737624A patent/EP1501787B1/en not_active Expired - Lifetime
- 2003-02-04 DK DK03737624T patent/DK1501787T3/en active
- 2003-02-04 WO PCT/US2003/003338 patent/WO2003066577A1/en not_active Ceased
- 2003-02-04 RS YUP-654/04A patent/RS65404A/en unknown
- 2003-02-04 PE PE2003000132A patent/PE20030986A1/en not_active Application Discontinuation
- 2003-02-04 AT AT03737624T patent/ATE309202T1/en not_active IP Right Cessation
- 2003-02-04 CA CA002474373A patent/CA2474373C/en not_active Expired - Fee Related
- 2003-02-04 PL PL03371664A patent/PL371664A1/en unknown
- 2003-02-04 US US10/503,501 patent/US20050084463A1/en not_active Abandoned
- 2003-02-04 EA EA200401054A patent/EA007297B1/en not_active IP Right Cessation
- 2003-02-04 ES ES03737624T patent/ES2250899T3/en not_active Expired - Lifetime
- 2003-02-04 HR HR20040677A patent/HRP20040677A2/en not_active Application Discontinuation
- 2003-02-04 MX MXPA04007660A patent/MXPA04007660A/en unknown
- 2003-02-04 JP JP2003565952A patent/JP4098249B2/en not_active Expired - Fee Related
- 2003-02-06 JO JO200315A patent/JO2356B1/en active
-
2004
- 2004-07-26 IS IS7372A patent/IS7372A/en unknown
- 2004-08-02 EC EC2004005217A patent/ECSP045217A/en unknown
- 2004-08-10 MA MA27820A patent/MA27108A1/en unknown
- 2004-09-07 NO NO20043739A patent/NO20043739L/en not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JO2356B1 (en) | N-biphenyl(substituted methyl) aminocycloalkanecarboxamide derivatives | |
| EP1476419A4 (en) | N-BIPHENYLMETHYL AMINOCYCLOALCANECARBOXAMIDE DERIVATIVES | |
| WO2005004810A3 (en) | Arylsulfonamide derivatives | |
| ECSP088692A (en) | COMPOUNDS BASED ON IMIDAZOL, COMPOSITIONS THAT INCLUDE THE SAME AND METHODS OF THEIR USE | |
| WO2004019868A3 (en) | N-biarylmethyl aminocycloalkanecarboxamide derivatives | |
| ES2171768T3 (en) | OSEA RESORTION INHIBITORS AND VITRONECTINE RECEPTORS ANTAGONISTS. | |
| TR200200118T2 (en) | New combinations | |
| DE60303679D1 (en) | ELECTROPHYSIOLOGICAL ELECTRODE WITH SEVERAL POWER SUPPLY LINES | |
| MY135233A (en) | N-aryl-2-oxazolidinone-5-carboxamides and their derivatives and their use as antibacterials | |
| TW200509910A (en) | Substituted pyrazole derivatives and related compounds as bradykinin B1 receptor antagonists | |
| ATE461217T1 (en) | GLP-1 COMPOUNDS | |
| UY26482A1 (en) | BIPHENYL SULPHONAMIDES AS ANGIOTENSIN RECEPTOR ANTAGONISTS | |
| MXPA05010819A (en) | The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome. | |
| DE60327103D1 (en) | PHARMACEUTICAL FORMS CONTAIN A PROTON PUMP, A NAZID AND A BUFFER | |
| ECSP045407A (en) | BENZAZOLES SUBSTITUTED AND THE USE OF THE SAME AS INHIBITORS OF QUINASA RAF | |
| HN1998000155A (en) | MEDICINES | |
| NO20052894L (en) | 4-tetrazolyl-4-phenylpiperidine derivatives for the treatment of pain | |
| CY1111767T1 (en) | HYDROGENIC PRODUCED BENZO [C] THIOPHANE PRODUCERS AS IMMUNE REGULATORS | |
| BRPI0415709A (en) | therapeutic regimens for baff antagonists | |
| ECSP045153A (en) | METHOD AND COMPOSITION TO INCREASE THE POWER OF A NARCOTIC ANALGEST. | |
| WO2002099388A3 (en) | Benzodiazepine bradykinin antagonists | |
| ES2213707T3 (en) | STIMULATION OF OSEO GROWTH WITH A PEPTIDIC DERIVATIVE OF THROMBIN. | |
| ECSP066575A (en) | BRADIQUININE B1 RECEIVER ANTAGONISTS | |
| DE602005012806D1 (en) | Aminocyclopropancarbonsäureamidderivate als bradykininantagonisten | |
| UY28049A1 (en) | DERIVATIVES OF (6,7-DIHIDRO-5H-IMIDAZO (1,2-A) IMIDAZOL-3-SULPHONYLAMINE) -PROPIONAMIDE |